

November 11, 2021
Symbio Pharmaceuticals Limited
(Securities Code: 4582)
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Symbio announces selection of "Growth Market" as new market segment

Symbio Pharmaceuticals Limited (the "Company") today announced that its Board of Directors has today resolved to submit the application to select "Growth Market" as the market segment on which the Company will be listed when the Tokyo Stock Exchange, Inc. (the "TSE") implements the new market segments. The decision confirms the segment designation provided to the Company by the TSE in its notice to the Company regarding compliance with listing maintenance criteria for the new market categories. The designation provided by the TSE is based on information available as of June 30, 2021. The Company will adhere to the procedures and schedules set by the TSE applicable to the new segment.

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125